Banting Discovery Foundation

Annual report

FY

2023-24

Chair's message

> *Today, our mission is no different than it was for Banting, as every young scientist faces daunting competition to secure funding to initiate their research endeavours.*

Catharine Whiteside
Chair of the Board of Trustees

A message of amazement and reflection

When first joining the Banting Research Foundation Board in 2015, I was immediately struck by the hidden nature of its remarkable value and long-lasting impact in Canada. Over 99 years, by supporting the bold ideas of early career researchers across the spectrum of health and biomedical science, our Foundation has catalyzed the launch of the research programs by many of our most brilliant scientists. Today, our mission is no different than it was for Banting, as every young scientist faces daunting competition to secure funding to initiate their research endeavours.

Now appropriately renamed the Banting Discovery Foundation, proof of its impact is the truly spectacular lifetime contributions of our Awardees to mobilizing knowledge into health- and life-saving diagnoses, treatments and disease prevention.

One of our 2025 Centenary Celebration projects is to feature 100 Awardee Profiles and their impact. Among many, these include: Dr. Herbert D. Kay who in 1929 co-developed the Kay-Graham test used throughout the world to confirm pasteurization of milk that prevented the transmission of the tuberculosis bacteria in raw milk; Dr. André J. Cipriani whose research on Cobalt-60 radiation led to the first radiotherapy for cancer in 1951, treating millions across the globe; Dr. Eva W.M. MacDonald who co-developed the first simplified Pap test for cervical cancer in 1948 leading to wide scale population screening; and, Dr. Brenda Gallie (1983) whose eye cancer research identified the genetic basis for retinoblastoma, revolutionizing treatment that has saved the vision and lives of children around the world. We have much to celebrate and communicate.

With the extraordinary skill and vision of our Executive Director, Maurine Kwok, the Foundation has entered a new era of engaging our Awardees. Although the highly competitive and prestigious Banting Discovery Award is valuable, we can offer more to help fill the mentoring and networking gap experienced by Awardees in their early days as independent researchers. The new Mentorship Program is both a challenge and opportunity for the Board to advance the Foundation's role in building the innovation capacity necessary for Canada's health and economic future.

Many thanks to all who have contributed to the success of the Foundation this year through volunteer efforts and donations.

Warm welcome to our new Board members and incoming Chair.

Over the past 9 years, it has been a distinct honour and privilege to serve with our deeply committed Trustees who recognize the value of the Foundation and its potential for growth and continued impact.

– Catharine Whiteside,
Chair of the Board of Trustees

Who we are

In recognition of Banting and Best's discovery of insulin despite inadequate funding or equipment, the Banting Research Foundation was established in 1925 to provide financial support to burgeoning researchers at Canadian universities.

Renamed the Banting Discovery Foundation in April 2024 to clarify its role as a grant-giving charity, this change underscores our commitment to nurture today's medical milestones into tomorrow's miracles while promoting gender parity.

What we do

The Banting Discovery Award supports early-stage researchers within their first 3 years of an independent research-related appointment. Our seed grant program nurtures budding experts during a crucial period of scare funding and finite time, when they are on the precipice of defining themselves in their chosen field.

What does a Discovery Award provide:

Fuels research cycle

Supports the next generation of Canadian researchers

Confers prestige

Enhances credibility by recognizing young researchers' excellence and creativity

Spurs innovations

Funds impactful projects that transform health and disease knowledge into know-how

Mentorship Program

Since beginning their journeys in 2023, our Awardees embarked on a unique opportunity supported by our Foundation. No other funding organization in Canada offers young scientists a tailored investment catered to the individual needs and challenges of becoming productive researchers.

Mentors guide young scientists in professional development areas like research management, leadership, science communication, and knowledge translation, promoting interdisciplinary thinking. The program provides networking opportunities with previous Awardees and industry experts, serving as a powerful career catalyst.

We host bi-annual events, in-person workshops and regular virtual events. The next in-person mentoring event is planned for mid-2025 in Toronto to coincide with the centenary of the Foundation.

"I did not have a large network of peers within the Canadian scientific community. One of my goals was to build this network and the program helped with this! I was also able to use this network when suggesting reviewers for my recent tenure file."

– Dr. Lindsay Cahill (2020 awardee)
Memorial University

May 23, 2024 – Virtual Mentorship Check-in. What a good-looking group!

"I never would have thought to reach out to a mentor like this. I typically rely on a small group of senior mentors and seek advice from near-peers. Connecting with a mid-career researcher from a similar institution, however, has proven to be incredibly valuable."

– Dr. Ian Patterson (2022 awardee)
Trent University

Rediscover the Legacy of Banting

The Foundation held two events celebrating the 100th Anniversary of the Nobel Prize awarded to Banting and Macleod on October 26, 1923, for the discovery of insulin, highlighting its impact and legacy.

We were graced with the presence of our awardees and friends at our October 25, 2023 luncheon.

Clockwise left to right:

Back: 2009 Awardee Dr. Mark Bayfield (York University), 2023 Awardee Dr. Eva Kaufmann (Queen's University), Honourary Director Dr. Reinhart Reithmeier, Awardee 2023 Dr. Brice Kuimi (U of T), Board Chair Dr. Catharine Whiteside, 2023 Awardee Andrew Harris (Ottawa University), Dr. Minna Woo (Director of Banting & Best Diabetes Centre) Professor Scott Heximer (Former Chair of U of T Physiology Department), Executive Director Maurine Kwok, Awardee 2023 Dr. Faith Brennan (Queen's University).

A night to remember

We delved into the legacy of Dr. Frederick Banting, the man who said,

> **"Insulin does not belong to me; it belongs to the world."**

We explored his enduring values of access and equity that have shaped a century of work at the Banting Research Foundation. Topics of discussion included: mosquito-borne viruses, fungal infections, and the evolution of diabetes treatments.

On November 6, 2023, a public panel discussion moderated by Ivan Semeniuk, renowned science journalist, editor, and broadcaster, and a longtime staff reporter for The Globe and Mail.

Our distinguished Banting Discovery Awardees panel included:

Dr. Jayne Danska, immunologist and senior scientist in genetics and genome biology at the Hospital for Sick Children, professor of medicine and the Anne and Max Tanenbaum Chair in Molecular Medicine at the University of Toronto.

Dr. Margaret Hahn, MD, PhD, FRPCP, senior scientist at the Centre for Addiction and Mental Health, professor of psychiatry and Kelly and Michael Meighen Chair for Psychosis Prevention at the University of Toronto.

Dr. Jennifer Geddes-McAlister, associate professor and Canada Research Chair of molecular and cellular biology, and director of Bioinformatics at the University of Guelph.

Dr. Alanna Weisman, MD, PhD, FRCPC, clinician scientist and endocrinologist at the Leadership Sinai Centre for Diabetes, and assistant professor of medicine at the University of Toronto.

Dr. Ian Patterson, assistant professor of biological sciences at Brock University.

Hosted by **Dr. Gareth Lim**, an associate professor and Canada Research Chair in adipocyte development at the University of Montreal.

> *"It was a tremendous pleasure to hear about your working and your insights. Thank you for doing such a terrific job and rolling with the questions as they came your way. "*
>
> **– Ivan Semeniuk, Science Reporter at The Globe and Mail**

Our impact

1374

Discovery Award Grants

Since 1925, the Banting Discovery Foundation has conferred 1374 Discovery Award grants to early career biomedical researchers – many of which have gone on to make societal impacts in their field.

Our past awardees have been recognized for the significance and impact of their research, which include:

37 The Order of Canada

17 The Canada Gairdner Award

25 The Canadian Medical Hall of Fame

15 The Queen Elizabeth II Diamond Jubilee Medal

15 The Queen Elizabeth II Golden Jubilee Medal

11 The Canadian Medical Association F.N.G. Starr Award

Since 2000, a total of 151 researchers were conferred the Discovery Award.



82 males
69 females

Those 151 researchers came from across 30 Canadian universities.

2024 Discovery Award winners

"Our Discovery Awardees are rooted in disciplines ranging from basic science to public health to artificial intelligence. Investing in our most creative young scientists has never been more critical because their discoveries will shape our health and economy."

– Dr. Catharine Whiteside, Chair of the Board

The Foundation was thrilled to welcome the **Ontario Brain Institute** as a new funding partner in 2024.

"Our partnership with the Banting Discovery Foundation underscores our commitment to better brain health. Congratulations to this year's recipients."

– Dr. Tom Mikkelsen,
President and Scientific Director of the Ontario Brain Institute

The eight award winners of the 99th cohort each have received up to $30,000 in July 2024 to pursue their moonshot research projects. Their progress will be published in our next report.

Visit our website for more about the projects of our 2024 Discovery Awardees.

Gregory E.P. Pearcey

Memorial University of Newfoundland

Funded by a Banting – Ontario Brain Institute Discovery Award, Gregory is uncovering how the brain and nervous system control human movement, with implications for repair of movement after injury or disease.

Xian Wang

Queen's University

Funded by a Banting – Ontario Brain Institute Discovery Award, Xian is developing a microrobot to treat brain cancer.

Maryam Kebbe

University of New Brunswick

Funded by a Banting – Heaslip Foundation Discovery Award, Maryam studies how different diets affect the gut microorganisms in young children and babies and subsequently their health.

Jean-Philippe Leduc-Gaudet

Université du Québec à Trois-Rivières

Funded by a Banting Discovery Award – Jarislowsky Fellowship, Jean-Philippe investigates genes and cell-cell communications involved in skeletal muscle health, which has a significant impact on longevity and wellness.

Katie A. Wilson

Memorial University of Newfoundland

Funded by a Banting Discovery Award – Jarislowsky Fellowship, Katie applies computer modelling to help design therapies and diagnostic tools for a spectrum of ailments, including antibiotic-resistant bacterial infections and cancer.

Janie Coulombe

Université de Montréal

Funded by a Banting – CANSSI Discovery Award in Biostatistics, Janie is developing advanced statistical methods for more tailored treatment and monitoring of patients with high blood pressure.

Justin Slater

University of Guelph

Funded by a Banting – CANSSI Ontario Discovery Award in Biostatistics, Justin is using statistical methods and machine learning to estimate how hepatitis C transmits within a population, which will help us take preventative or corrective actions.

Karine Choquet

Université de Sherbrooke

Funded by a Banting Discovery Award, Karine is examining how certain mistakes in relaying a gene's instruction can contribute to aging and human diseases such as cancer and dementia.

2023-24 Mitacs-Postdoctoral Fellowships

Dr. Breanna Raymond

Simon Fraser University

Climate Crisis and Neonatal Sepsis

Dr. Breanna Raymond is an expert in applying 'omics techniques to understand how climate change impacts microbes living in changing environments. She joined the research team of Dr. Amy Lee, a 2022 Awardee and Assistant Professor in Molecular Biology and Biochemistry at Simon Fraser University. This collaboration includes Centre of Excellence Prevention of Organ Failure, a not-for-profit organization focused on omics-based biomarker development to better predict, diagnose, and treat disease.

Newborns are highly susceptible to infectious diseases and developing sepsis, a disease with high mortality due to a weakened immune system in the very young. Climate change threatens to exacerbate this issue by increasing the spread of infectious pathogens and further inhibiting host immune functioning. The goal of the project is to better understand the intersection between these two leading threats to global human health: climate change and infectious disease. This research will allow for future development of improved diagnosis, prevention, and control strategies for neonatal sepsis.

Dr. Larissa Krokosky

Brock University

Using insect-specific viruses to prevent the transmission of arthropod-borne viruses

Dr. Larissa Krokovsky is a researcher in arthropod-borne viruses. She joined the research team of Dr. Ian Patterson, a 2022 Discovery Award-Jarislowsky Fellowship awardee and Assistant Professor of Virology in the Department of Biological Sciences at Brock University. This collaboration includes Entomogen Inc., an environmental consulting company based in St. Catharines that specializes in medical entomology.

The project aims to evaluate a novel method of reducing the transmission of arthropod-borne viruses in mosquitoes and to learn more about West Nile virus infections in Canadian mosquitoes. These studies will support a new strategy to use insect-specific viruses to prevent mosquitoes from transmitting dangerous viruses and develop more tools for surveillance and prevention of future outbreaks in Canada.

Impacts made by our 2023 Discovery awardees

Dr. Faith Brennan

Queen's University

Dr. Faith Brennan is an assistant professor and principal investigator of the neurotrauma laboratory at Queen's University. She has received numerous grants and awards, most recently the JP Bickell Foundation Medical Research Award, Mark S. Lodge Spinal Cord Research Award, and Banting Research Foundation Discovery Award all in 2023. Her lab has two main research themes: neuroinflammation and peripheral neuro-immune interactions. Dr. Brennan uses mice models to examine traumatic brain injuries and spinal cord injuries and how they differ with biological sex.

Whole genome sequencing, which determines the complete DNA sequence, was performed on tissue samples taken from spinal-cord injured mice and sham-injured mice. Both groups were either fed normal chow or chow containing a drug that reduces microglial cell levels - immune cells specific to the brain and spinal cord. All genes that are active at a given time point make up what is called a transcriptome. Spatial transcriptome analyses were done on the brains and spinal cords of male and female mice, revealing significant differences based on region and sex after neurotrauma. Motor and sensory tasks were used to monitor the recovery process, illuminating a sex difference potentially linked with the molecular and transcriptional variation.

Acknowledging biological differences between the sexes leads to improved recovery outcomes and bridges the knowledge gap in medical research that historically focused solely on male subjects. At the time of writing, Dr. Brennan's lab is entirely female-led and run, all members including students are women. Not only is Dr. Brennan paving the way for personalized trauma recovery, but she is also uplifting the next generation of female neuroscientists.

Dr. Sergio Crespo-Garcia

Université de Montréal

Dr. Sergio Crespo-Garcia is an assistant professor with the School of Optometry at Université de Montréal. He has received multiple awards and distinctions from Spain, Germany, Japan, Canada, and the USA. Most recently he received HMR Foundation Publication Prize on Cell Metabolism in 2021. Dr. Crespo-Garcia's lab focuses on retinal cell biology, studying the cells that make up the light-sensitive tissue located at the back of the eye. By examining gene expression, cell metabolism, and age-related changes in the retina, Dr. Crespo-Garcia aims to address macular degeneration - a condition that becomes more common with age and is more prevalent in individuals with high blood pressure or obesity - which can lead to blindness.

In the retina, chemical processes that build up and break down molecules produce homocysteine, a substance that comes from breaking down another molecule called methionine. The buildup of homocysteine is harmful and can damage delicate blood vessels in the retina. To transform homocysteine back to methionine, the body requires folate

- vitamin B9. With age, the genes that maintain proper functioning of folate receptors on retinal cells are no longer expressed, which can lead to age-related macular degeneration.

The eyes are a part of the central nervous system, meaning that retinal damage can lead to subsequent neurodegeneration. Further exploration of homocysteine and folate metabolism could unlock therapeutics that prevent or reverse vision loss and advance the study of retinal and brain related pathologies. Dr. Crespo-Garcia's research is advancing the preservation of vision quality, enabling people to see clearly into their golden years.

Dr. Andrew Harris

Carleton University

Dr. Andrew Harris is an assistant professor in the department of mechanical and aerospace engineering and the principal investigator of the Cell and Tissue Engineering Laboratory at Carleton University. He received the Banting Discovery Award in 2023 and the Research Achievement Award from Carleton University in 2024. Dr. Harris's lab takes a materials science perspective on biological systems, working with bioreactors - devices or systems that maintain controlled, sterile environmental conditions for biological and chemical reactions. In collaboration with Canadian Blood Services and an Ontario startup company - Artinus AI - Dr. Harris's research aims to develop a bioreactor that produces platelets, the blood cells that cause clotting.

To make platelets externally, a thorough understanding of the environment that early-stage platelets develop in along with the mechanical forces exerted on them is required. Three factors were considered: the stiffness of the material the cells grow on, limiting cell movement, and the pressure exerted on the cells. Treatment of acute and chronic platelet disorders require platelets from donated blood which keep for approximately five days stored at room temperature and carries the risk of causing an autoimmune response. Current methods for creating platelets externally do not make enough cells for even a single transfusion, which highlights the necessity of Dr. Harris's work.

Aside from the urgent clinical need for platelets that poses a significant burden on the Canadian Healthcare system, the novel methods used in Dr. Harris's project translate to research in stem cell biology, biochemistry, and biophysics. Cell manufacturing and therapeutics are a part of regenerative medicine which aims to repair or replace damaged tissues and organs. Regenerative medicine has applications in treating certain types of cancer, degenerative conditions, and traumatic injuries. In essence, Dr. Harris's lab is establishing foundational methodologies for a wide array of uses.

Dr. Eva Kaufmann

Queen's University

Dr. Eva Kaufmann is a trained immunologist and assistant professor at Queen's University. Dr. Kaufmann won the August 2018 Relève étoile Jacques-Genest award, the Werner Müller Prize in 2018, the Banting Discovery Award in 2023, and was appointed the Canadian Research Chair in Immunology and Inflammation in 2024. Her current research focuses on the long-term impact of mold exposure on the immune system. The most common pathogenic species of fungi to humans and animals is Aspergillus fumigatus. Exposing mice to A. fumigatus, via nasal or abdominal administration at a high dosage, leads to the total loss of early-stage immune cells found in bone marrow. Using a very low dose of mold via exposure through the nose activated immune cells, causing them to build up in the bone marrow.

Although low doses of mold exposure do not result in visible symptoms of disease, long-term exposure results in the accumulation of activated immune cells and a state of chronic inflammation. There is a possibility that low dose exposure to mold affects the body's ability to protect itself. Dr. Kaufmann and her team are testing this hypothesis using live animal models. She also suspects that mold exposure can alter the DNA leading to epigenetic reprogramming, producing either positive or maladaptive immunological consequences.

Approximately 40% of households experience mold exposure. Particularly in dwellings that have high humidity, poor ventilation, or experienced a leak or flooding. Lower income households disproportionately experience mold exposure resulting in health inequalities. Dr. Kaufmann's lab is addressing a new research focus, environmental exposures on infection and asthma, which is timely given the rise in climate related environmental changes such as smoke from wildfires and mold formation after flooding. This research equips us to better address future health challenges in the face of a changing global climate.

"I sincerely thank the Banting Research Foundation and Mitacs for supporting the development of this research program through the Discovery Award."

Dr. Brice Batomen Kuimi

University of Toronto

Dr. Brice Batomen Kuimi is an assistant professor of epidemiology at Dalla Lana School of Public Health at the University of Toronto. He received the Young Scientist Award of the International Council on Alcohol, Drugs, and Traffic Safety (ICADTS) and the "Coup de cœur" award by the Réseau de recherche en sécurité routière du Québec (RRSRQ) in 2022. One of Dr. Kuimi's research interests is road safety with a focus on injury prevention. Cities like Toronto, Ontario face transportation concerns in light of growing populations. Vision Zero, a movement that envisions zero traffic-related fatalities or severe injuries, is being carried out in Toronto and Dr. Kuimi examined the shortcomings of Vision-Zero policy implementation.

The two main objectives of Dr. Kuimi's study was assessing cycling infrastructure effectiveness and tracking trends and seasonal cycles in traffic incidents across space and time. Verification of the data made publicly available by the City of Toronto for cycling infrastructure was manually done using street imagery services, while collision data from the Toronto Police Service was cross-referenced with City of Toronto data. Both the cycling infrastructure and collision datasets lacked reliable, detailed, representative traffic volume data. Properly assess the impact that Vision-Zero initiatives have relies on quality data collection, prompting Dr. Kuimi to develop a model that pinpoints patterns of when and where collisions occur.

Traffic collisions are a preventable burden on healthcare systems and a leading cause of premature death. City initiatives are at risk of being clustered in high-income neighborhoods, resulting in public safety disparities. Dr. Kuimi's research emphasizes the importance of rigorous data collection to better engineer road safety measures for drivers, cyclists, and pedestrians in hopes of achieving road safety parity.

Dr. Erwan Pernet

Université du Québec à Trois-Rivières

Dr. Erwan Pernet is an assistant professor in the department of medical biology and the principal investigator of the Neonatal Pulmonary Immunity lab at Université du Québec à Trois-Rivières. His lab focuses on the cellular and molecular mechanisms regulating neonatal pulmonary immune responses, filling a research gap as most studies are done on adults. Infants born prematurely are highly susceptible to disease, such as bronchopulmonary dysplasia (BPD) which causes inflammation, tissue damage, and halts lung development. Dr. Pernet hypothesizes that high oxygen exposure to premature lungs results in hyperoxia-induced oxidative stress, leading to the production of Type I interferon (IFN-I) - a group of immune signaling proteins - causing inflammation and suppressing lung growth.

Mice pups were exposed to higher than normal and normal concentrations of oxygen then their lungs were harvested at different time points after birth. Their lungs were examined for IFN-I and other immune signaling molecules. Subsequently, lung tissue samples were examined under a microscope, and the immune cells present in the tissue were characterized. Particular focus was given to macrophages and epithelial cells as they are present in higher numbers in the neonatal lung. A synthetic molecule was exposed to the macrophages and epithelial cells to induce IFN-I production.

Learning the precise mechanisms that underlie BPD is necessary to find potential new therapeutics. In Canada, 8% of all births are premature. If a high-risk newborn contracts BPD, they will have serious health complications such as increased likelihood of long-term respiratory struggles and increased susceptibility to infection during infancy. Dr. Pernet's research caters to an underserved population: newborns, improving health outcomes and advancing neonatal care.

Dr. Marie-Claude Sincennes

Institut National de la Recherche Scientifique

Dr. Erwan Pernet is an assistant professor in the department of medical biology and the principal investigator of the Neonatal Pulmonary Immunity lab at Université du Québec à Trois-Rivières. His lab focuses on the cellular and molecular mechanisms regulating neonatal pulmonary immune responses, filling a research gap as most studies are done on adults. Infants born prematurely are highly susceptible to disease, such as bronchopulmonary dysplasia (BPD) which causes inflammation, tissue damage, and halts lung development. Dr. Pernet hypothesizes that high oxygen exposure to premature lungs results in hyperoxia-induced oxidative stress, leading to the production of Type I interferon (IFN-I) - a group of immune signaling proteins - causing inflammation and suppressing lung growth.

Mice pups were exposed to higher than normal and normal concentrations of oxygen then their lungs were harvested at different time points after birth. Their lungs

were examined for IFN-I and other immune signaling molecules. Subsequently, lung tissue samples were examined under a microscope, and the immune cells present in the tissue were characterized. Particular focus was given to macrophages and epithelial cells as they are present in higher numbers in the neonatal lung. A synthetic molecule was exposed to the macrophages and epithelial cells to induce IFN-I production.

Learning the precise mechanisms that underlie BPD is necessary to find potential new therapeutics.

In Canada, 8% of all births are premature. If a high-risk newborn contracts BPD, they will have serious health complications such as increased likelihood of long-term respiratory struggles and increased susceptibility to infection during infancy. Dr. Pernet's research caters to an underserved population: newborns, improving health outcomes and advancing neonatal care.

Our supporters

Up to $50,000

The Madison Foundation
The Heaslip Foundation

Up to $5,000

Catharine Whiteside

Up to $3,000

Sheelagh Whittaker
Richard Nunn
Anonymous

Up to $500

Anonymous
Andrea Donlan
Gerry Lokash
Shanon Grauer

Our appreciation to the University of Toronto Temerty Faculty of Medicine for providing us with office space.

A huge thank you to each and every one of our volunteers, who are inspirational, amazing, hardworking and powerful!

Financial Health

Balance Sheet (As of June 30)	**2024 ($)**	**2023 ($)**
Assets		
Cash	92,328	31,781
HST recoverable	17,559	9,263
Investment, at fair value	5,772,361	5,333,435
Artwork	20,000	20,000
Total assets	**5,902,248**	**5,394,479**
Liabilities		
Accounts payable and accrued liabilities	30,701	49,121
Fund balances		
General funds	1,149,393	961,205
Restricted fund endowment fund	150,000	106,140
Endowment fund	4,572,154	4,278,013
Total fund balances	**5,871,547**	**5,345,358**
	5,902,248	**5,394,479**

The Balance Sheet is an excerpt of the audited financial statements by Baker Tilly WM LLP, Chartered Professional Accountants. Detailed FY2024 Financial Statements are available upon request.

Condensed statement of revenue and expenses and changes in fund balances (Year ended June 30)	**2024 ($)**	**2023 ($)**
Revenue		
Investment income, net	743,616	368,597
Donations	186,202	62,374
Gain on disposal of assets	-	53,740
Total Revenue	**929,818**	**484,711**
Expenses		
Grants awarded to new investigators	229,983	178,339
Program development	9,032	37,231
Professional fees	8,523	8,108
Office, general and administrative	156,091	115,752
Total Expenses	**403,629**	**339,430**
Excess (deficiency) of revenue over expenses for the year	**526,189**	**145,281**
Fund balances, beginning of year	5,345,358	5,200,077
Fund balances, end of year	**5,871,547**	**5,345,358**

The Condensed Statement is an excerpt of the audited financial statements by Baker Tilly WM LLP, Chartered Professional Accountants. Detailed FY2024 Financial Statements are available upon request.

2024
Discovery Award selection panel

Dr. Anthony Gramolini, Panel Chair
Department of Physiology,
University of Toronto

Dr. Walid A. Houry, Scientific Officer
Departments of Biochemistry and
Chemistry, University of Toronto

Dr. Mahavir Agarwal
Department of Psychiatry, University
of Toronto, and Medical Head, Clinical
Research, Schizophrenia Division,
Centre for Addiction & Mental Health

Dr. Brian Ballios
Department of Ophthalmology & Vision
Sciences, The J. Ardeth Hill – Fighting
Blindness Canada Professor in Ocular
Genetics Research, University of Toronto

Dr. Linda Chelio
Head, Biochemistry, Immunology &
Microbiology, University of Saskatchewan

Dr. Amy Greer
Department of Biology,
Trent University

Dr. Salim Islam
Microbiology & Biotechnology,
INRS-Institut Armand Frappier,
Banting Awardee 2018

Dr. Karen Kopciuk
Cumming School of Medicine,
University of Calgary

Dr. Paul Kurdyak
Director, Adult Psychiatry and Health
Systems; Senior Scientist, Institute for
Mental Health Policy Research, Centre for
Addiction and Mental Health

Dr. Bowen Li
Drug Development & Disease Diagnostics,
Faculty of Pharmacy, University of Toronto

Dr. Zihang Lu
Public Health Sciences,
Queen's University

Dr. Marco Magalhaes
Laboratory Medicine & Pathiobiology,
Faculty of Dentistry, University of Toronto

Dr. Bouchra Nasri
Department of Social & Preventative
Medicine, University of Montreal

Dr. Andrew Nicholson
Department of Psychology,
University Ottawa,
Banting Awardee 2021

Dr. Aaron Reinke
Department of Molecular Genetics,
University of Toronto

Board of Directors

Catharine Whiteside, CM MD PhD
Chair of Board 2015-2024
Emerita Professor,
Former Dean of Medicine,
University of Toronto

Alain Beaudet, MD PhD
Vice-Chair
Former President, Canadian Institutes of Health Research (CIHR)
Former President & CEO, Fonds de la recherche en santé du du Québec (FRSQ)

Shanon Grauer
Secretary & Chair of the Governance Committee
Counsel, INQ Law

Gerald Lokash
Treasurer
Retired C.A./Chartered Professional Accountant and Business Advisor

Richard Nunn
Chair, Audit Committee
Retired Senior Client Service Partner, Deloitte

Andrea Donlan
VP, MacMillan Vantage Policy Group

Donald Guloien
Founder of Guloien Capital
Former President & CEO of Manulife

Trang Hoang, OC CM PhD
Discovery Awardee 1988
Professor, Department of Pharmacology, Faculty of Medicine, Université de Montréal

Linda Li, PT, PhD, CRC
Professor & Harold Robinson/Arthritis Society Chair in Arthritic Diseases
Department of Physical Therapy, University of British Columbia

Marc Pouliot, PhD
Discovery Awardee 2000
Professor, Department of Microbiology-Infectious Diseases and Immunology
School of Medicine, Laval University

Jesse Vincent-Herscovici
CEO, Axeyls

Juan Carlos Zuniga-Pflucker
Professor & Former Chair, Department of Immunology, University of Toronto and Senior Scientist, Sunnybrook Research Institute

Sheelagh Whittaker
Former CEO, Canadian Satellite Communications Inc.

Support burgeoning researchers as they help position Canada as a leading innovation incubator on the world stage.

Your investment would be celebrated as a cornerstone of the Banting Discovery Foundation's 100th anniversary in mid-2025.

Donate

Click to donate

Banting
Discovery Foundation

bantingresearchfoundation.ca
info@bantingresearchfoundation.ca